Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4565336
Max Phase: Preclinical
Molecular Formula: C86H127N13O28S
Molecular Weight: 1823.09
Molecule Type: Unknown
Associated Items:
ID: ALA4565336
Max Phase: Preclinical
Molecular Formula: C86H127N13O28S
Molecular Weight: 1823.09
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C86H127N13O28S/c1-4-5-28-63(81(113)99-70(51-78(109)110)85(117)96-65(79(87)111)47-57-25-19-18-20-26-57)95-83(115)68(49-59-52-90-62-29-24-23-27-61(59)62)93-73(102)53-91-80(112)66(46-56(2)3)97-82(114)67(48-58-32-34-60(35-33-58)127-128(120,121)122)98-84(116)69(50-77(107)108)94-75(104)55-126-45-43-124-41-39-89-74(103)54-125-44-42-123-40-38-88-71(100)37-36-64(86(118)119)92-72(101)30-21-16-14-12-10-8-6-7-9-11-13-15-17-22-31-76(105)106/h18-20,23-27,29,32-35,52,56,63-70,90H,4-17,21-22,28,30-31,36-51,53-55H2,1-3H3,(H2,87,111)(H,88,100)(H,89,103)(H,91,112)(H,92,101)(H,93,102)(H,94,104)(H,95,115)(H,96,117)(H,97,114)(H,98,116)(H,99,113)(H,105,106)(H,107,108)(H,109,110)(H,118,119)(H,120,121,122)/t63-,64-,65-,66-,67-,68-,69-,70-/m0/s1
Standard InChI Key: LXWCNCKGNPJZAA-ASNOGBRRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1823.09 | Molecular Weight (Monoisotopic): 1821.8634 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sensfuss U, Kruse T, Skyggebjerg RB, Uldam HK, Vestergaard B, Huus K, Vinther TN, Reinau ME, Schéele S, Clausen TR.. (2019) Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists., 62 (3): [PMID:30624060] [10.1021/acs.jmedchem.8b01558] |
Source(1):